Xencor | XNCR - Net Income


Xencor reported $-6.03M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 2.53B 83M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
J&J USD 5.12B 36M Dec/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Xencor USD -6.03M 24.8M Sep/2025